Edgewise Therapeutics (EWTX) Expected to Post Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Edgewise Therapeutics to post earnings of ($0.4677) per share for the quarter. Individuals can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Edgewise Therapeutics (NASDAQ:EWTX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.04. On average, analysts expect Edgewise Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Edgewise Therapeutics Stock Performance

Shares of NASDAQ:EWTX opened at $38.38 on Tuesday. Edgewise Therapeutics has a one year low of $12.30 and a one year high of $48.40. The stock has a fifty day moving average of $38.59 and a 200-day moving average of $33.65. The company has a market capitalization of $4.13 billion, a PE ratio of -23.12 and a beta of 0.30.

Insider Buying and Selling at Edgewise Therapeutics

In related news, insider Alan J. Russell sold 200,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $39.41, for a total transaction of $7,882,000.00. Following the transaction, the insider directly owned 24,555 shares of the company’s stock, valued at approximately $967,712.55. The trade was a 89.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 21.30% of the company’s stock.

Hedge Funds Weigh In On Edgewise Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Orbimed Advisors LLC lifted its position in shares of Edgewise Therapeutics by 3.3% in the second quarter. Orbimed Advisors LLC now owns 15,518,492 shares of the company’s stock worth $203,447,000 after purchasing an additional 496,771 shares in the last quarter. RA Capital Management L.P. grew its position in Edgewise Therapeutics by 5.3% during the third quarter. RA Capital Management L.P. now owns 10,428,437 shares of the company’s stock valued at $169,149,000 after purchasing an additional 525,804 shares in the last quarter. Paradigm Biocapital Advisors LP grew its position in Edgewise Therapeutics by 6.0% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 6,541,210 shares of the company’s stock valued at $162,320,000 after purchasing an additional 371,079 shares in the last quarter. Siren L.L.C. increased its stake in Edgewise Therapeutics by 16.2% in the 4th quarter. Siren L.L.C. now owns 4,529,990 shares of the company’s stock valued at $112,412,000 after buying an additional 632,891 shares during the period. Finally, Morgan Stanley increased its stake in Edgewise Therapeutics by 234.7% in the 4th quarter. Morgan Stanley now owns 2,910,881 shares of the company’s stock valued at $72,234,000 after buying an additional 2,041,203 shares during the period.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on EWTX shares. Raymond James Financial reaffirmed a “strong-buy” rating and set a $66.00 target price on shares of Edgewise Therapeutics in a report on Monday, June 1st. Leerink Partners set a $52.00 price objective on shares of Edgewise Therapeutics in a research note on Tuesday, June 16th. Evercore reissued an “outperform” rating and issued a $55.00 target price on shares of Edgewise Therapeutics in a research report on Monday, July 20th. The Goldman Sachs Group lifted their target price on shares of Edgewise Therapeutics from $20.00 to $32.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Edgewise Therapeutics in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Edgewise Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $48.75.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.